Novo Nordisk closed at $38.26, up 1.95% and outpacing a 0.22% loss on the S&P 500, as the drugmaker heads into its upcoming earnings disclosure with analysts raising their estimates. The company is expected to report earnings per share of $0.8, down 21.57% from the prior-year quarter, on revenue of $11.41 billion, a 2.79% decline. For the full fiscal year, the Zacks Consensus Estimates predict earnings of $3.53 per share and revenue of $46.1 billion, changes of -10.86% and -1.46% respectively from the former year. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.41% higher, and Novo Nordisk holds a Zacks Rank of #3 (Hold). The stock trades at a Forward P/E ratio of 10.62, a discount to its industry's 15.82, with a PEG ratio of 1.23 versus the Large Cap Pharmaceuticals industry average of 1.86.
Novo Nordisk A/SAnalysts raised EPS estimates over the last 30 days ahead of earnings, with the stock trading at a discount to its industry.
